Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Venture Life ( (GB:VLG) ) is now available.
Venture Life Group has granted options over 1,000,000 ordinary shares to Chief Digital and Technology Officer Peter Jackson under its 2023 Long Term Incentive Plan, with an exercise price of 58.76p and vesting after three years post-publication of 2028 results. The options are subject to malus and clawback provisions, a seven-year exercise window after vesting, and performance conditions linked to total shareholder return and earnings per share.
The award underscores Venture Life’s use of equity-based incentives to align senior management with shareholder value creation and long-term performance metrics. By tying vesting to both market and earnings measures, the company reinforces a performance-driven culture, which may support its strategic execution in the competitive global self-care and consumer healthcare markets.
The most recent analyst rating on (GB:VLG) stock is a Hold with a £67.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.
Spark’s Take on GB:VLG Stock
According to Spark, TipRanks’ AI Analyst, GB:VLG is a Neutral.
Venture Life’s stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.
To see Spark’s full report on GB:VLG stock, click here.
More about Venture Life
Venture Life Group is an international consumer self-care company operating in the global consumer healthcare sector, focused on commercialising over-the-counter products. Its portfolio spans women’s intimate health, ENT care, energy and glucose management, and hormonal lifecycle support, with products sold through pharmacies, health and beauty retailers, grocery chains, and e-commerce in the UK, Ireland, the USA, and via international distributors.
The company’s brands include Balance Activ for women’s intimate healthcare, Earol for ear, nose and throat care, Lift and Glucogel for energy and hypoglycaemia management, and the Health & Her range for hormonal support. These products are typically recommended by pharmacists or healthcare practitioners and positioned within the growing global self-care market, reinforcing Venture Life’s role as a specialist in proactive healthy living solutions.
Average Trading Volume: 328,727
Technical Sentiment Signal: Buy
Current Market Cap: £84.53M
Find detailed analytics on VLG stock on TipRanks’ Stock Analysis page.